Showing results (231-240 of 456) with videos related to
Sort By:
Pageof 46
Journal of the National Cancer Institute|October 19, 2013
Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapySusan Halabi, Chen-Yen Lin, Eric J Small, et al.Cancers|December 10, 2021
The Impact of Enzalutamide on the Prostate Cancer Patient Experience: A Summary Review of Health-Related Quality of Life across Pivotal Clinical TrialsBertrand Tombal, Arnulf Stenzl, David Cella, et al.The Journal of Urology|March 1, 1988
M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urotheliumC N Sternberg, A Yagoda, H I Scher, et al.The Journal of Urology|March 1, 1988
Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for extravesical urinary tract tumorsH I Scher, A Yagoda, H W Herr, et al.The Prostate|July 10, 2023
Prognostic value of neutrophil-to-lymphocyte ratio in patients with metastatic castration-resistant prostate cancer receiving prostate-specific membrane antigen targeted radionuclide therapyJudith Stangl-Kremser, Michael Sun, Benedict Ho, et al.Journal for Immunotherapy of Cancer|January 10, 2023
New prognostic model in patients with advanced urothelial carcinoma treated with second-line immune checkpoint inhibitorsAristotelis Bamias, Axel Merseburger, Yohann Loriot, et al.British Journal of Cancer|August 1, 1994
Docetaxel (Taxotere), a novel taxoid, in the treatment of advanced colorectal carcinoma: an EORTC Early Clinical Trials Group StudyC N Sternberg, W W ten Bokkel Huinink, J F Smyth, et al.Cancer Treatment Reviews|June 24, 2020
Immune-checkpoint inhibitors and metastatic prostate cancer therapy: Learning by making mistakesMélanie Claps, Alessia Mennitto, Valentina Guadalupi, et al.Clinical Genitourinary Cancer|May 6, 2014
Sequential targeted therapy after pazopanib therapy in patients with metastatic renal cell cancer: efficacy and toxicityJoaquim Bellmunt, Francesc Pons, Abigail Foreshew, et al.Oncology|October 2, 2013
Larotaxel with Cisplatin in the first-line treatment of locally advanced/metastatic urothelial tract or bladder cancer: a randomized, active-controlled, phase III trial (CILAB)Cora N Sternberg, Iwona A Skoneczna, Daniel Castellano, et al.Pageof 46